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Summary A total of 558 patients with a range of localization-related epilepsy
syndromes starting treatment in a single centre were followed over a period of up to
20 years. Overall, 343 (62%) patients became seizure free for 12 months or more
(responders), 92% of whom (57% of total population) remained in remission until the
end of follow-up. Only 27 (5%) responders relapsed and subsequently developed
refractory epilepsy. The remaining 215 (38%) patients never became seizure free for
any 12-month period. There were no significant differences in outcome between
cryptogenic (56% remission) and symptomatic (57% remission) epilepsies. Patients
with underlying cortical atrophy (71% remission; p < 0.05) or cerebrovascular disease
(70% remission; p < 0.01) did better, while those with traumatic brain injury (35%
remission; p < 0.001) did worse than the remainder of the symptomatic group.
Remission rates in patients with cortical dysplasias (60%), hippocampal atrophy
(50%) and primary brain tumors (52%) appeared no different from those with other
symptomatic epilepsies. Overall, 20—40% patients with each epilepsy syndrome
reported no further seizures after starting AED treatment including 21% with hippo-
campal atrophy and 33% with cortical dysplasia. More than 50% of patients developing
localization-related epilepsy during adolescence or in adulthood had a good outcome.
Prognosis in those with underlying hippocampal atrophy or cortical dysplasia was not
always bad.
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The natural history of seizure disorders should be
taken into consideration in any study of outcome.
The key to accurate assessment of prognosis is
recruitment of patients at the same point in the
course of the disorder.1 Specialist epilepsy clinics* Corresponding author. Tel.: +44 141 211 2572;
fax: +44 141 334 9329.
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(M.J. Brodie).
1059-1311/$ — see front matter # 2005 BEA Trading Ltd. Published
doi:10.1016/j.seizure.2005.04.002have a higher representation of patients with
refractory epilepsy and cross sectional studies in
such populations invariably report low rates of sei-
zure freedom. This factor accounts for the per-
ceived poor prognosis of epilepsy in much of the
early literature. Longitudinal, population-based
studies in patients with new onset epilepsy provide
a more reliable assessment of response to treat-
ment.2—5
With the widespread use of high resolution brain
magnetic resonance imaging it has been possible to
identify underlying structural abnormalities in manyby Elsevier Ltd. All rights reserved.
Localization-related epilepsies 319patients with localization-related epilepsy.6 Our
understanding of the prognosis of these sympto-
matic epilepsies, nonetheless, is largely based on
studies carried out in specialist centers. Thus, it is
widely believed that certain types of symptomatic
epilepsies, such as those associated with hippocam-
pal atrophy and malformations of cortical develop-
ment, which are frequently encountered in these
clinic populations, almost invariably respond poorly
to pharmacotherapy.7—9 However, in most parts of
the world epilepsy is treated at its onset by non-
specialists. Many patients who respond to antiepi-
leptic drugs (AED) treatment do not undergo brain
imaging. It is only when they prove refractory to a
range of AEDs that referral to a specialist centre is
made and subtle structural abnormalities such as
hippocampal atrophy are identified.10
Populations of patients with newly diagnosed
epilepsy are, therefore, required to assess accu-
rately the response to AED treatment in sympto-
matic epilepsy syndromes. We carried out an
outcomes study in patients with localization-related
epilepsies diagnosed, treated and followed up at a
single centre over a 20-year period. This study
follows up our preliminary observations published
in 2000 which was made in a smaller cohort of
patients.4 Nearly twice as many patients have
now been followed up over a longer time period.
Particular focus in this report has been placed on
remission in patients with specific symptomatic epi-
lepsy syndromesMethods
Adolescent and adult patients with suspected sei-
zure disorders were referred to the first seizure
service at the Western Infirmary, Glasgow, Scotland,
by general practitioners, accident and emergency
physicians and other clinicians over a 20-year per-
iod. A structured protocol was used to collect clin-
ical information and detailed histories were
obtained from patients and witnesses regardingTable 1 Treatment outcomes in patients with newly diagn
All localization
related epilepsies
Response 343 62%
Remission 316 57%
Relapse 27 5%
Uncontrolled 215 38%
Total 558 100%
Response, seizure-free for at least 12 months; remission, control ma
after initial response; uncontrolled, never free of seizures for any
a Idiopathic localization-related epilepsies were included with crsuspected seizures. Electroencephalography was
performed as clinically indicated, and brain imaging
was undertaken if localization related epilepsy was
suspected. When a diagnosis of epilepsy was made,
the first ever AED was prescribed and outcomes
were monitored over a period of years. Patients
were considered to have responded to treatment
if they had no seizures for a minimum of 12 months
on an unchanged treatment schedule. Remission
was defined as having no further seizures after
responding to treatment. Relapse occurred in
responders in whom initial control was lost and
whose epilepsy subsequently became pharmacore-
sistant. Patients who continued to report seizures
were, by definition, considered to have uncon-
trolled epilepsy. The extent of control was assessed
at the time of the patient’s last hospital visit. End of
follow up was 1st May 2003, when the last patient
had been attending the clinic for 2 years.
Epidemiological data were collected by review of
research case notes. Seizure types and syndromes
were classified at the time of analysis according to
the guidelines of the International League against
Epilepsy.11,12 Data were collected on an electronic
spreadsheet and analysed using Minitab for Windows
(version 13.32). Patients who did not return for
follow up or were persistently non-adherent to their
prescribed medication were excluded from analysis.
The x2 test was used to analyse categorical data and
the Bonferroni method was used to correct for
multiple comparisons. The Mann—Whitney test
was used for analysis of non-parametric continuous
data.Results
Between August 1981 and May 2001, 890 patients
were diagnosed with epilepsy, all of whom were
prescribed AED treatment. A total of 625 (70%)
patients were classified as having localization-
related epilepsy. Sixty-seven patients (11%) were
excluded from analysis owing to insufficient fol-osed localization-related epilepsies.
Cryptogenic
epilepsiesa
Symptomatic
epilepsies
195 62% 148 61%
179 57% 137 56%
16 5% 11 5%
119 38% 96 39%
314 100% 244 100%
intained until the end of follow-up; relapse, refractory epilepsy
12 months.
yptogenic group for analysis of outcomes.
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Table 2 Remission rates and immediate responders* in each epilepsy syndrome.
Total Remission Immediate
respondersa
Idiopathic
Benign epilepsy with centrecephalic spikes 6 5 (83%) 4 (67%)
Benign occipital epilepsy 4 3 (75%) 0 (0%)
Benign partial epilepsy of childhood 1 1 (100%) 0 (0%)
Symptomatic
MTLE with HA 14 7 (50%) 3 (21%)
Cerebrovascular disease 63 44 (70%)* 25 (40%)
Cerebral atrophy 42 30 (71%)** 17 (40%)
Post-traumatic epilepsy 65 23 (35%)*** 13 (20%)
Primary brain tumors 25 13 (52%) 5 (20%)
Cortical malformations 15 9 (60%) 5 (33%)
Vascular lesion 7 4 (57%) 2 (29%)
Other lesions 13 7 (54%) 5 (38%)
MTLE with HA, mesial temporal lobe epilepsy with hippocampal atrophy.
a Immediate responders never had another seizure after starting treatment.
* p < 0.05 compared with rest of symptomatic group.
** p < 0.01 compared with rest of symptomatic group.
*** p < 0.001 compared with rest of symptomatic group.low-up information. Treatment outcomes were
known for the remaining 558 (89%) patients. This
cohort comprised 296 (53%) males and 262 (47%)
females. The median age at onset (first seizure) was
33 years (range 1—93 years) and that at diagnosis
was 35 years (range 11—93 years). Patients reported
a median of 5 (range 1 to >100) seizures before
stating treatment. None had previously received an
AED for any indication.
Overall, 303 (54%) patients were designated as
having cryptogenic epilepsy. A further 244 (44%) hadTable 3 Clinical characteristics of patients with newly dia
atrophy.
Sex Age at
first
seizure
(years)
Age at
starting
treatment
(years)
Number
of
pretreatment
seizures
Seizure
types
1 Male 59 59 15 GTCS
2 Female 6 50 12 GTCS
3 Female 34 34 >100 SPS/GTCS
4 Male 45 50 >100 GTCS
5 Male 54 56 30 CPS
6 Male 27 27 2 SPS/GTCS
7 Female 30 30 3 CPS
8 Male 37 38 35 CPS
9 Male 29 30 2 GTCS
10 Male 10 16 >100 CPS/GTCS
11 Female 21 21 28 SPS/GTCS
12 Male 57 58 36 CPS/GTCS
13 Female 17 18 6 GTCS
14 Male 20 20 2 CPS/GTCS
SPS, simple partial seizures; CPS, complex partial seizures; GTCS,
a Patients suffering no further seizures after starting treatment.a structural lesion identified on brain magnetic
resonance or computerised tomographic imaging
and were classified as having symptomatic epilepsy.
The remaining 11 (2%) patients had idiopathic loca-
lization-related epilepsy syndromes (6 benign epi-
lepsy with centrotemporal spikes, 4 benign occipital
epilepsy, 1 benign partial epilepsy of childhood.)
A total of 343 (62%) responded to treatment by
becoming seizure free for a period of 12 months or
more (Table 1). Thirty-nine responders had a recur-
rence of seizures, in 27 of whom control was nevergnosed mesial temporal lobe epilepsy and hippocampal
Side Treatment
outcome
Successful
therapy
Time to
remission
(months)
Duration
of
remission
(months)
Right Remission Monotherapy 32 238
Left Refractory
Right Refactory
Right Relapse Monotherapy 12 137
Right Remissiona Monotherapy 6 52
Left Refractory
Left Remissiona Monotherapy 12 88
Right Refractory
Left Remissiona Monotherapy 9 78
Left Refractory
Right Remission Monotherapy 27 32
Right Remission Monotherapy 17 36
Right Remission Duotherapy 27 25
Left Refractory
generalised tonic clonic seizures.
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Table 4 Clinical characteristics of patients with newly diagnosed localization-related epilepsy and malformations of cortical development.
Sex Age at
first
seizure
(years)
Age at
starting
treatment
(years)
No of
pre-treatment
seizures
Seizure
types
Brain imaging Treatment
outcome
Successful
therapy
Time to
remission
(months)
Duration of
remission
(months)
1 Male 14 15 8 GTCS Left parieto-temporal heterotopia Remission Monotherapy 15 229
2 Female 27 28 28 SPS/GTCS Multiple tubers Refractory
3 Female 51 51 1 SPS/GTCS Left temporal hippocampal atrophy
with cortical dysplasia
Remissiona Monotherapy 12 72
4 Male 19 20 12 GTCS Left temporal cortical dysplasia Remission Monotherapy 16 68
5 Female 33 33 15 SPS/GTCS Right temporal cortical dysplasia Refractory
6 Male 22 23 6 GTCS Bilateral occipital band heterotopia Remissiona Monotherapy 12 78
7 Male 21 22 2 SPS/GTCS Left frontal cortical dysplasia Refractory
8 Male 15 15 3 GTCS Right frontal cortical dysplasia Remissiona Monotherapy 12 72
9 Male 17 17 4 SPS/GTCS Right temporal cortical dysplasia Refractory
10 Female 14 17 3 CPS/GTCS Left fronto-parietal cortical dysplasia Remissiona Monotherapy 11 82
11 Male 16 16 7 GTCS Right frontal cortical dysplasia Relapse Monotherapy 16 29
12 Male 14 14 5 SPS/GTCS Lissencephaly, developmental 5th and
6th ventricle
Remission Duotherapy 37 27
13 Male 15 16 4 GTCS Left occipital heterotopia Remission Monotherapy 20 42
14 Male 36 36 2 GTCS Left occipital heterotopia Remissiona Monotherapy 12 37
15 Male 1 22 >100 CPS Bilateral periventricular nodular
heterotopia
Refractory
SPS, simple partial seizures; CPS, complex partial seizures; GTCS, generalised tonic clonic seizures.
a Patients suffering no further seizures after starting treatment.
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entire cohort (8% of all responders). Thus, seizures
were well controlled until the end of follow up in 316
(57%) patientswhowere regarded as having achieved
remission. The remaining 215 (38%) patients never
achieved seizure freedom for any 12-month period.
No significant differenceswere observed in outcomes
between patients with symptomatic and cryptogenic
epilepsies (Table 1). Monotherapy was successful in
315 (92%) of the 343 responders, 77% of whom were
taking their first AED. In patients failing initial mono-
therapy, a second regimen produced seizure control
in 59 (17%) patients (42 alternative monotherapy, 17
duotherapy).
Outcomes in the various localization-related epi-
lepsy syndromes are listed in Table 2. Patients with
cerebral atrophy (71% remission, p < 0.05), and
cerebrovascular disease (70% remission, p < 0.01)
did better, while those with traumatic brain injury
(35% remission, p < 0.001) did worse than the
remainder of the symptomatic group. Those with
underlying hippocampal atrophy (Table 3; 50%
remission) or malformations of cortical develop-
ment (Table 4; 60% remission) fared no worse than
the other types of symptomatic epilepsy.
A number of patients suffered no further seizures
after starting AED treatment. These ‘‘immediate
responders’’ constituted 20—40% patients with each
specific epilepsy syndrome (Table 2). Interestingly,
21% patients with hippocampal atrophy and 33%
with cortical dysplasia fell into this category. The
probability of achieving an immediate response was
highest for patients with epilepsy due to underlying
cerebrovascular disease (40%) or cerebral atrophy
(40%).
Patients who relapsed or remained uncontrolled
had been seizure free for a median of 21 months
(range 12—97 months). The risk of relapse was not
significantly different between patients with cryp-
togenic (n = 15) or symptomatic (n = 12) epilepsies.
Only one patient each with hippocampal atrophy
and cortical dysplasia has relapsed to date. Twenty-
six of the 27 patients who relapsed were receiving
monotherapy with 23 taking their first AED.Discussion
In this population of patients with newly diagnosed
localization-related epilepsy, 62% responded to
treatment by becoming seizure free for 12 months
or more. Overall, 57% of the complete cohort
remained in remission until the end of follow up.
More than half of these patients suffered no further
seizures immediately after starting treatment. The
probability of a good outcome was highest inpatients with underlying cerebral atrophy and cer-
ebrovascular disease, and lowest for those with
post-traumatic epilepsy. Only 8% of initial respon-
ders went on to develop refractory epilepsy. The
remaining 38% patients never achieved complete
seizure control for any 12-month period and could
be regarded as having refractory epilepsy de novo.4
Mesial temporal lobe epilepsy is the commonest
localization-related epilepsy syndrome, with hippo-
campal atrophy occurring in 50—70% of patients
reporting uncontrolled seizures.13 The incidence
of refractory epilepsy in all patients with such hip-
pocampal pathology, however, is unknown. Hospi-
tal-based case series have reported remission rates
ranging from 11 to 42% with AED treatment depend-
ing on rates of referral from primary or secondary
care.7—9,14,15 Recent studies employing volumetry
have identified hippocampal atrophy in patients
with good seizure control16,17 and even in those
without clinical or electroencephalographic evi-
dence of mesial temporal lobe epilepsy.18,19 Thus,
the relationship of hippocampal atrophy with
refractory epilepsy, and indeed, with seizures them-
selves, is far from clear. Eight of the 14 patients who
developed symptomatic epilepsy on the basis of
underlying hippocampal atrophy responded to AED
therapy with only one relapsing to date. Three
patients never had another seizure after commen-
cing AED therapy. Our data, therefore, suggest that
the overall probability of remission in patients with
this syndrome may be no worse than with other
lesional epilepsies.
Malformations of cortical development have
been increasingly recognised as the underlying
cause of localization-related seizures with the wide-
spread use of high quality brain imaging techni-
ques.20 In recent years, there has been a greater
understanding of their genetic bases, clinical pre-
sentations, and epileptogenic mechanisms.21 How-
ever, the prevalence of these abnormalities in the
general population and in patients with epilepsy in
not known. Subtle anatomical anomalies have been
demonstrated in asymptomatic relatives of patients
with cortical dysplasias and epilepsy.22 Ten of the 15
patients with newly diagnosed cortical dysplasias
responded to treatment with only one relapsing.
Again, five of these patients never had another
seizure after starting AED therapy. Thus, as with
hippocampal atrophy, the relative contribution of
these abnormalities to refractory epilepsy remains
unclear.
The mechanism of action of the traditional AEDs
and many of the newer ones are thought to be
known.23 Why they show varying efficacy in patients
with the same underlying pathology is unclear. Sev-
eral hypotheses on the substrates underlying the
Localization-related epilepsies 323evolution of drug resistant epilepsy have been pro-
posed.24 These include ontogenic abnormalities in
brain maturation, epilepsy induced alterations in
networking, neuronal and glial properties in seizure
prone areas such as the hippocampus, and the phe-
nomenon of kindling and reorganisation of cortical
tissue in response to seizure induced disturbances in
oxygen supply. It is likely that response to drug
treatment is governed by a number of genetic and
environmental influences.25 Genetic polymorphisms
cause variations in the levels and activity of drug
metabolising enzymes and transporter molecules
and may affect the distribution and concentration
of AEDs.26,27 Polymorphisms of drug targets may
alter the affinity and activity of individual drugs.
Similarly environmental factors, including lifestyle
issues, such as abuse of proconvulsant recreational
drugs, can affect the efficacy of AEDs. In such a
complex multifactorial environment individual fac-
tors are likely to have limited predictive value. The
epilepsy syndrome in an adult population is only one
such variable.References
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